Pharmacophore mapping, molecular docking and QSAR studies of structurally diverse compounds as CYP2B6 inhibitors

Molecular Simulation

Volumn 36, Issue 11, 2010, Pages 887-905

  Roy, Partha Pratim ^a   Roy, Kunal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

cytochrome 2B6; G PLS; GFA; pharmacophore; QSAR

Indexed keywords

CYTOCHROME 2B6; G/PLS; GFA; PHARMACOPHORES; QSAR;

DOCKING; HYDROGEN; HYDROGEN BONDS; MOLECULAR GRAPHICS; MOLECULAR MODELING; SPLINES;

PHARMACODYNAMICS;

EID: 77958168199     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927022.2010.492834     Document Type: Article

References (61)

1. D.R. Nelson, L. Koymans, T. Kamataki, J.J. Stegeman, R. Feyereisen, D.J. Waxman, M.R. Waterman, O. Gotoh, M.J. Coon, R.W. Estabrook, I.C. Gunsalus, and D.W. Nebert, P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics 6 (1996), pp. 1-42. (Pubitemid 26096749)
2. D.R. Nelson, D.C. Zeldin, S.M. Hoffman, L.J. Maltais, H.M. Wain, and D.W. Nebert, Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants, Pharmacogenetics 14 (2004), pp. 1-18.
3. D.R. Nelson, Gene nomenclature by default, or BLASTing to babel, Hum. Genomics 2 (2005), pp. 196-201.
4. S. Ekins, M. Vandenbranden, B.J. Ring, J.S. Gillespie, T.J. Yang, H.V. Gelboin, and S.A. Wrighton, Further characterization of the expression in liver and catalytic activity of CYP2B6, J. Pharmacol. Exp. Ther. 286 (1998), pp. 1253-1259. (Pubitemid 29135537)
5. L. Gervot, B. Rochat, J.C. Gautier, F. Bohnenstengel, H. Kroemer, V. de Berardinis, H. Martin, P. Beaune, and I. de Waziers, Human CYP2B6: Expression, inducibility and catalytic activities, Pharmacogenetics 9 (1999), pp. 295-306. (Pubitemid 29376373)
6. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 caucasians, J. Pharmacol. Exp. Ther. 270 (1994), pp. 414-423. (Pubitemid 24229655)
7. M. Mimura, T. Baba, H. Yamazaki, S. Ohmori, Y. Inui, F.J. Gonzalez, F.P. Guengerich, and T. Shimada, Characterization of cytochrome P450 2B6 in human liver microsomes, Drug Metab. Dispos. 21 (1993), pp. 1048-1056. (Pubitemid 23348341)
8. D.M. Stresser and D. Kupfer, Monospecific antipeptide antibody to cytochrome P-450 2B6, Drug Metab. Dispos. 27 (1999), pp. 517-525. (Pubitemid 29177646)
9. E.L. Code, C.L. Crespi, B.W. Penman, F.J. Gonzalez, T.K. Chang, and D.J. Waxman, Human cytochrome P4502B6: Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation, Drug Metab. Dispos. 2510 (1997), pp. 985-993.
10. C. Bathelt, R.D. Schmid, and J. Pleiss, Regioselectivity of CYP2B6: Homology modeling, molecular dynamics simulation, docking, J. Mol. Model 8 (2002), pp. 327-335. (Pubitemid 36153495)
11. H. Hanna, J.R. Reed, F.P. Guengerich, and P.F. Hollenberg, Expression of human cytochrome P450 2B6 in E. coli: Characterization of catalytic activity and expression levels in human liver, Arch. Biochem. Biophys. 376 (2000), pp. 206-216.
12. L.M. Hesse, K. Venkatakrishnan, M.H. Court, L.L. von Moltke, S.X. Duan, R.I. Shader, and D.J. Greenblatt, CYP2B6 mediates the in vitro hydroxylation of bupropion: Potential drug interactions with other antidepressants, Drug Metab. Dispos. 28 (2000), pp. 1176-1183.
13. S. Miksys, C. Lerman, P.G. Shields, D.C. Mash, and R.F. Tyndale, Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain, Neuropharmacology 45 (2003), pp. 122-132. (Pubitemid 36700458)
14. D. Nolan, E. Phillips, and S. Mallal, Efavirenz and CYP2B6 polymorphism: Implications for drug toxicity and resistance, Clin. Infect. Dis. 42 (2006), pp. 408-410. (Pubitemid 43122321)
15. S.R. Faucette, H. Wang, G.A. Hamilton, S.L. Jolley, D. Gilbert, C. Lindley, B. Yan, M. Negishi, and E. LeCluyse, Regulation of CYP2B6 in primary human hepatocytes by prototypical inducers, Drug Metab. Dispos. 32 (2004), pp. 348-358. (Pubitemid 38263894)
16. R.L. Walsky, A.V. Astuccio, and R.S. Obach, Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, J. Clin. Pharmacol. 46 (2006), pp. 1426-1438. (Pubitemid 44704203)
17. M. Turpeinen, H. Raunio, and O. Pelkonen, The functional role of CYP2B6 in human drug metabolism: Substrates and inhibitors in vitro, in vivo and in silico, Curr. Drug Metab. 7 (2006), pp. 705-714. (Pubitemid 44509677)
18. U.S. Svensson and M. Ashton, Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin, Br. J. Clin. Pharmacol. 48 (1999), pp. 528-535. (Pubitemid 29454233)
19. M. Rotger, S. Colombo, H. Furrer, G. Bleiber, T. Buclin, B.L. Lee, O. Keiser, J. Biollaz, L. Decosterd, and A. Telenti, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients, Pharmacogenet. Genomics 15 (2005), pp. 1-5. (Pubitemid 43205520)
20. J.K. Coller, N. Krebsfaenger, K. Klein, K. Endrizzi, R. Wolbold, T. Lang, A. Nussler, P. Neuhaus, U.M. Zanger, M. Eichelbaum, and T.E. Murdter, The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxytamoxifen in human liver, Br. J. Clin. Pharmacol. 54 (2002), pp. 157-167. (Pubitemid 35024939)
21. T.K. Chang, G.F. Weber, C.L. Crespi, and D.J. Waxman, Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes, Cancer Res. 53 (1993), pp. 5629-5637.
22. S.L. Mo, Y.H. Liu, W. Duan, M.Q. Wei, J.R. Kanwar, and S.F. Zhou, Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6, Curr. Drug Metab. (2009).
23. H. Wang and L.M. Tompkins, CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme, Curr. Drug Metab. 9 (2008), pp. 598-610.
24. E.D. Kharasch, D. Mitchell, and R. Coles, Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity, J. Clin. Pharmacol. 48 (2008), pp. 464-474. (Pubitemid 351389115)
25. R.L. Walsky, A.V. Astuccio, and R.S. Obach, Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, J. Clin. Pharmacol. 46 (2006), pp. 1426-1438. (Pubitemid 44704203)
26. J. Kumagai, T. Fujimura, S. Takahashi, T. Urano, T. Ogushi, K. Horie-Inoue, Y. Ouchi, T. Kitamura, M. Muramatsu, B. Blumberg, and S. Inoue, Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer, Prostate 67 (2007), pp. 1029-1037. (Pubitemid 46983333)
27. S. Ekins, G. Bravi, B.J. Ring, T.A. Gillespie, J.S. Gillespie, M. Vandenbranden, S.A. Wrighton, and J.H. Wikel, Three-dimensional quantitative structure-activity relationship analyses of substrates for CYP2B6, J. Pharmacol. Exp. Ther. 288 (1999), pp. 21-29. (Pubitemid 29113468)
28. Q. Wang and J.R. Halpert, Combined 3D quantitative structure- activity relationship analysis of cytochrome P450 2B6 substrates and protein homology modeling, Drug Metab. Dispos. 30 (2002), pp. 86-95. (Pubitemid 34016945)
29. D.F. Lewis, B.G. Lake, Y. Ito, and P. Anzenbacher, Quantitative structure-activity relationships (QSARs) within cytochromes P450 2B (CYP2B) subfamily enzymes: The importance of lipophilicity for binding and metabolism, Drug Metabol. Drug Interact. 21 (2006), pp. 213-231. (Pubitemid 43971439)
30. L.E. Korhonen, M. Turpeinen, M. Rahnasto, C. Wittekindt, A. Poso, O. Pelkonen, H. Raunio, and R.O. Juvonen, New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on Three-dimensional and quantitative structure-activity relationship (3D-QSAR) analysis, Br. J. Pharmacol. 150 (2007), pp. 932-942. (Pubitemid 46536632)
31. S.C. Gay, M.B. Shah, J.C. Talakad, K. Maekawa, A.G. Roberts, P.R. Wilderman, L. Sun, J.Y. Yang, S.C. Huelga, W.X. Hong, Q. Zhang, C.D. Stout, and J.R. Halpert, Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4- Chlorophenyl)imidazole at 2.0A ° resolution, Mol. Pharmacol. 77 (2010), pp. 529-538.
32. Discovery Studio 2.1 is a product of Accelrys Inc, San Diego, CA, USA.
33. Y. Kurogi and O.F. Guner, Pharmacophore modeling and Threedimensional database searching for drug design using catalyst, Curr. Med. Chem. 8 (2001), pp. 1035-1055. (Pubitemid 32633658)
34. A.K. Debnath, Pharmacophore mapping of a series of 2,4-diamino- 5-deazapteridine inhibitors of mycobacterium avium complex dihydrofolate reductase, J. Med. Chem. 45 (2002), pp. 41-53.
35. P. Kahnberg, M.H. Howard, T. Liljefors, M. Nielsen, E.O. Nielsen, O. Sterner, and I. Pettersson, The use of a pharmacophore model for identification of novel ligands for the benzodiazepine binding site of the GABAA receptor, J Mol Graph Model 23 (2004), pp. 253-261. (Pubitemid 39463104)
36. J. Faragalla, J. Bremner, D. Brown, R. Griffith, and A. Heaton, Comparative pharmacophore development for inhibitors of human and rat 5-a-reductase, J. Mol. Graph. Model 22 (2003), pp. 83-92. (Pubitemid 36694496)
37. S. Ekins, G. Bravi, J.H. Wikel, and S.A. Wrighton, Threedimensional- quantitative structure-activity relationship analysis of cytochrome P-450 3A4 substrates, J. Pharmacol. Exp. Ther. 291 (1999), pp. 424-433. (Pubitemid 29451619)
38. A. Smellie, S.L. Teig, and P. Towbin, Poling: Promoting conformational variation, J. Comp. Chem. 16 (1995), pp. 171-187.
39. R. Kristam, V.J. Gillet, R.A. Lewis, and D. Thorner, Comparison of conformational analysis techniques to generate pharmacophore hypotheses using catalyst, J. Chem. Inf. Model. 45 (2005), pp. 461-476. (Pubitemid 40635354)
40. J. Li, T. Ehlers, J. Sutter, S. Varma-O'Brien, and J. Kirchmair, CAESAR: A new conformer generation algorithm based on recursive buildup and local rotational symmetry consideration, J. Chem. Inf. Model. 47 (2007), pp. 1923-1932. (Pubitemid 47561140)
41. Y.H. Hung and Y.S. Liao, Applying PCA and fixed size LS-SVM method for large scale classification problems, Inf. Technol. J. 7 (2008), pp. 890-896.
42. T. Fawcett, An introduction to ROC analysis, Pattern Recognit. Lett. 27 (2006), pp. 861-874.
43. Cerius2 version 4.10 is a product of Accelrys, Inc., San Diego, USA.
44. J.T. Leonard and K. Roy, On selection of training and test sets for the development of predictive QSAR models, QSAR Comb. Sci. 25 (2006), pp. 235-251. (Pubitemid 350213175)
45. K. Roy and A.S. Mandal, Development of linear and nonlinear predictive QSAR models and their external validation using molecular similarity principle for anti-HIV indolyl aryl sulfones, J. Enzyme Inhib. Med. Chem. 23 (2008), pp. 980-995.
46. Y. Fan, L.M. Shi, K.W. Kohn, Y. Pommier, and J.N. Weinstein, Quantitative structure-antitumor activity relationships of camptothecinanalogues: Cluster analysis and genetic algorithmbased studies, J. Med. Chem. 44 (2001), pp. 3254-3263. (Pubitemid 32917105)
47. D. Rogers and A.J. Hopfinger, Application of genetic function approximation to quantitative structure-activity relationship and quantitative structure-property relationship, J. Chem. Inf. Comput. Sci. 34 (1994), pp. 854-866.
48. W.J. Dunn III and D. Rogers, Genetic Partial Least Squares in QSAR, in Genetic Algorithms in Molecular Modeling, J. Devillers, ed., Academic Press, London, 1996, pp. 109-130.
49. K. Hasegawa, Y. Miyashita, and K. Funatsu, GA strategy for variable selection in QSAR studies: GA-based PLS analysis of calcium channel antagonists, J. Chem. Inf. Comput. Sci. 37 (1997), pp. 306-310. (Pubitemid 127603530)
50. G.W. Snedecor and W.G. Cochran, Statistical Methods, Oxford & IBH Publishing, New Delhi, 1967.
51. S. Wold, PLS for Multivariate Linear Modeling, in Chemometric methods in molecular design, H. van de Waterbeemd, ed., VCH, Weinheim, 1995, pp. 195-218.
52. A.K. Debnath, Quantitative structure-activity relationship (QSAR): A versatile tool in drug design, in Combinatorial Library Design and Evaluation: Principles, Software Tools, and Applications in Drug Discovery, A.K. Ghose and V.N. Viswanadhan, eds., Marcel Dekker, New York, 2001, pp. 73-129.
53. K. Roy, On some aspects of validation of predictive QSAR models, Expert. Opin. Drug. Discov. 2 (2007), pp. 1567-1577.
54. P.P. Roy and K. Roy, On some aspects of variable selection for partial least squares regression models, QSAR Comb. Sci. 27 (2008), pp. 302-313.
55. K. Roy and P.P. Roy, Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors, Chem. Biol. Drug Des. 72 (2008), pp. 370-382.
56. I. Mitra, P.P. Roy, S. Kar, P. Ojha, and K. Roy, On further application of r2 m as a metric for validation of QSAR models, J. Chemometrics 24 (2010), pp. 22-33.
57. K. Roy and S. Paul, Exploring 2D and 3D QSARs of 2, 4-diphenyl-1, 3-oxazolines for ovicidal activity against tetranychus urticae, QSAR Comb. Sci. 28(4) (2008), pp. 406-425.
58. S. Ekins, M. Iyer, M.D. Krasowski, and E.D. Kharasch, Molecular characterization of cyp2b6 substrates, Curr. Drug Metab. 9 (2008), pp. 363-373. (Pubitemid 352025191)
59. P.P. Roy, J.T. Leonard, and K. Roy, Exploring the impact of the size of training sets for the development of predictive QSAR models, Chemom. Intell. Lab. Sys. 90 (2008), pp. 31-42. (Pubitemid 350213175)
60. L. Eriksson, J. Jaworska, A.P. Worth, M.T. Cronin, R.M. McDowell, and P. Gramatica, Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs, Environ. Health Perspect. 111 (2003), pp. 1361-1375. (Pubitemid 37021142)
61. D. Itokawa, T. Nishioka, J. Fukushima, T. Yasuda, A. Yamauchi, and H. Chuman, Quantitative structure-activity relationship study of binding affinity of azole compounds with CYP2B and CYP3A, QSAR Comb. Sci. 26 (2007), pp. 828-836. (Pubitemid 47121259)